MedTrace Logo

Phase I Single and Multiple Escalating Dose Study of RGN1016 in Healthy Male Subjects

NCT02820155 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2016-07-06

No results posted yet for this study

Summary

This is a double-blind, randomized, placebo-controlled, dose-escalating, single dose and multiple dose study.

Conditions

  • Healthy

Interventions

DRUG

RGN1016

Stage I: single oral dose Stage II: multiple oral dose (QD, 7days)

DRUG

Placebo

Stage I: single oral dose Stage II: multiple oral dose (QD, 7days)

Sponsors & Collaborators

  • National Taiwan University

    collaborator OTHER

  • National Taiwan University Hospital

    lead OTHER

Principal Investigators

  • Ming-Jang Chiu · Neurology department of National Taiwan University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-06-30
Primary Completion
2017-02-28
Completion
2017-02-28

Countries

  • Taiwan

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02820155 on ClinicalTrials.gov